RESET-MG: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Generalized Myasthenia Gravis
Status: Recruiting
Location: See all (14) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Age ≥18 and ≤70 years of age
• Diagnosis of MG with generalized muscle weakness meeting criteria as defined by the MGFA class II, III , IVa, and IVb.
• Diagnosis of seropositive (autoantibodies AChR, MuSK and/or LRP4) or seronegative MG
Locations
United States
California
University of California Irvine
RECRUITING
Orange
UC Davis, Department of Neurology
RECRUITING
Sacramento
University of California, San Francisco
RECRUITING
San Francisco
Colorado
University of Colorado
RECRUITING
Aurora
Florida
Mayo Clinic Florida
RECRUITING
Jacksonville
Illinois
Northwestern Memorial Hospital
RECRUITING
Chicago
Kansas
University of Kansas Medical Center
RECRUITING
Kansas City
Massachusetts
University of Massachusetts Chan Medical School
RECRUITING
Worcester
Minnesota
Mayo Clinic - Rochester
RECRUITING
Rochester
New York
Columbia University
RECRUITING
New York
University of Rochester Medical Center
RECRUITING
Rochester
Oregon
Oregon Health & Science University
RECRUITING
Portland
Texas
Houston Methodist Hospital
RECRUITING
Houston
Washington
Swedish Neuroscience Research
RECRUITING
Seattle
Contact Information
Primary
Cabaletta Bio
clinicaltrials@cabalettabio.com
267 759 3100
Time Frame
Start Date: 2024-12-17
Estimated Completion Date: 2029-09
Participants
Target number of participants: 12
Treatments
Experimental: CABA-201
AChR Antibody-Positive Cohort AChR Antibody-Negative Cohort
Related Therapeutic Areas
Sponsors
Leads: Cabaletta Bio